Y-mAbs Therapeutics (YMAB) Now Covered by Canaccord Genuity

Research analysts at Canaccord Genuity initiated coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note issued on Tuesday, The Fly reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 54.00% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Cowen reissued a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Tuesday. BTIG Research initiated coverage on Y-mAbs Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock.

YMAB stock opened at $19.48 on Tuesday. Y-mAbs Therapeutics has a twelve month low of $19.20 and a twelve month high of $31.00.

In related news, Director James Healy acquired 500,000 shares of the firm’s stock in a transaction on Friday, September 21st. The shares were bought at an average cost of $16.00 per share, with a total value of $8,000,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ashu Tyagi acquired 430,174 shares of the firm’s stock in a transaction on Tuesday, September 25th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $6,882,784.00. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 961,424 shares of company stock worth $15,382,784.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: What is Considered a Good Return on Equity (ROE)?

The Fly

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply